Related Experiment Video
Updated: Nov 18, 2025
15:00
Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies
Published on: February 3, 2023
2.8K
Using ActionADE to create information continuity to reduce re-exposures to harmful medications: study protocol for a
Jeffrey P Hau1,2, Penelope M A Brasher2, Amber Cragg1,2
1Department of Emergency Medicine, University of British Columbia, 855 West 12th Avenue, Vancouver, British Columbia, V5Z 1M9, Canada.
Trials
|February 6, 2021
Summary
Preventing repeat adverse drug events is crucial. ActionADE improves information continuity across health sectors, reducing medication errors and enhancing patient adherence through integrated health information technology.
Area of Science:
- Health Informatics
- Pharmacovigilance
- Clinical Trials
Background:
- Repeat exposure to culprit medications frequently causes preventable adverse drug events (ADEs).
- Current health information technologies often lack interoperability, hindering the sharing of ADE information across systems.
- ActionADE is a novel system designed for rapid ADE documentation and standardized information sharing across health sectors.
Purpose of the Study:
- To evaluate the impact of information continuity on preventing culprit medication re-dispensation after adverse drug reactions.
- To assess the effect of information continuity on patient adherence to culprit medications.
- To leverage a health information technology implementation for pragmatic randomized controlled trials.
Main Methods:
- Two parallel, triple-blind randomized controlled trials involving 3600 adults in British Columbia, Canada.
- ActionADE software documents ADEs and uses an algorithm for patient eligibility and trial allocation.
- Experimental arm: ActionADE transmits ADE information to PharmaNet for display at community pharmacies; Control arm: information remains in local records.
Main Results:
- Primary outcome for the main trial: re-dispensation of culprit or same-class medication within 12 months.
- Primary outcome for the secondary trial: adherence to culprit medication over 12 months.
- Secondary outcomes include health services utilization and mortality.
Conclusions:
- This study demonstrates the potential of integrated health information technology to prevent repeat adverse drug events.
- Findings may inform policy and investment decisions for health IT interoperability.
- The ActionADE implementation serves as a model for conducting pragmatic randomized controlled trials.
Related Concept Videos
01:19Pharmacovigilance
1.4K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.4K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
265
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
265
01:01Dosage Regimen: Fixed Dose
2.2K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.2K
01:28Dosage Regimens: Designs and Approaches
122
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
122
01:26Drug Administration and Therapy Phases: Overview
967
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
967
01:11Blinding
3.7K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.7K